Placebo rituximab

DRUG2 trials

Sponsors

GlaxoSmithKline, Hoffmann-La Roche

Conditions

Rheumatoid ArthritisSjogren's Syndrome

Phase 2

Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome

CompletedNCT02631538

GlaxoSmithKlineSjogren's Syndrome

Start: 2016-02-17End: 2020-06-23Updated: 2021-06-09

A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis

CompletedNCT02693210

Hoffmann-La RocheRheumatoid Arthritis

Start: 2001-02-28End: 2004-08-31Updated: 2016-11-01

Related Papers

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

JCI Insight2022-12-07105 citations

Validation of the PROFAD-SSI-SF in Patients with Primary Sjögren's Syndrome with Organ Involvement: Results of Qualitative Interviews and Psychometric Analyses.

2022-10-138 citations

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

BMJ Open2019-03-01110 citations